Biotech Values

[DewDiligence]

ICVX -55% on_weak_immunogenic_response to COVID-vaccine:

https://www.globenewswire.com/news-release/2022/03/25/2410205/0/en/Icosavax-Announces-Topline-Interim-Phase-1-2-Results-for-IVX-411-Against-SARS-CoV-2.html

Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).

“While IVX-411 was immunogenic and well-tolerated in these initial topline data, the level of response was below our expectations given what we know about VLPs, including from clinical studies in COVID-19 and from our own preclinical data,” said Niranjan Kanesa-thasan, M.D., Chief Medical Officer of Icosavax.

The share price is now down 2/3 from its mid-2021 IPO (#msg-165173004).